Zolunicant  (Synonyms: MM-110; (±)​-18-Methoxycoronaridine)

Zolunicant (MM-110) is a potent inhibitor against nicotinic α3β4 receptors with an IC₅₀ of 0.90 μM to combat addiction. Zolunicant can decrease the self-administration of several addictive agents including morphine, methamphetamine, nicotine, and ethanol in rat model. Zolunicant can be studied as a potential research for multiple forms of agent abuse^[1]. Zolunicant also reveals a potent leishmanicide effect against Leishmania amazonensis^[2].

Zolunicant (18-MC; 0.01-100 μM) 对烟碱型 α3β4 受体具有抑制活性，IC₅₀ 为 0.90 μM^[1]。
。Zolunicant (18-MCOR; 0-20 μg/mL; 24 h) 还对 L. amazonensis 感染的巨噬细胞显示出抗鞭毛体活性^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Zolunicant (18-MC；静脉注射；每天 0-20 μg；14 天) 通过阻断缰核-脚间通路中的 α3β4 烟碱受体来减少吗啡的自我给药^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

368.47

C₂₂H₂₈N₂O₃

188125-42-0

固体

White to off-white

Room temperature in continental US; may vary elsewhere.

• [1]. Pace CJ, et al. Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration. European journal of pharmacology. 2004;492(2-3):159-67.  [Content Brief]

  [2]. Delorenzi JC, et al. In vitro activities of iboga alkaloid congeners coronaridine and 18-methoxycoronaridine against Leishmania amazonensis. Antimicrob Agents Chemother. 2002;46(7):2111-5.  [Content Brief]

  [3]. Glick SD, et al. 18-Methoxycoronaridine acts in the medial habenula and/or interpeduncular nucleus to decrease morphine self-administration in rats. European journal of pharmacology. 2006;537(1-3):94-8.  [Content Brief]